Jamie Kasuboski

OMX Ventures LLC (OMX Ventures) is a venture capital firm founded in 2020. The firm is headquartered in Lincolnshire, Illinois.

Glyphic Biotechnologies Inc is an American biotechnology company that develops a protein sequencing platform to provide researchers with new insights into biology and disease. Glyphic Biotechnologies was founded by Joshua Yang and Daniel Estandian, with Joshua Yang serving as the CEO since incorporation.

Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau.

ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier.

Boehringer Ingelheim Venture Fund is an evergreen venture capital fund which seeks investment opportunities in biotech across the globe. It targets investments unrelated to Boehringer Ingelheim’s key therapeutic areas. Specifically, it focuses on start-up companies engaging in patient care enhancements through pioneering science including new therapeutic platforms, new generation vaccines, and new generation protein & antibody technologies, among others. The fund makes initial equity investments of EUR 500 thousand to EUR 3 million in seed or series A rounds. It also makes follow-on investments over a five to seven year time period, bringing the total investment size per company to an amount of EUR 10 million to EUR 15 million. The fund seeks to acquire minority stakes (usually greater than or equal to 10%) in target companies, as well as a seat on the board.